You are inaccurate. First of all they have more data on the 27th also with Alzheimer’s your goal is to look at data past the 25 days. More like 6 months...
It beat SAVA data at their 25 day mark if you read the abstract.
At 6 months they will have a much better P value.
I’m invested in several AD stocks. I don’t know how anyone here can argue the data so far is bad. If so you should invest in AD stocks or bio stocks.
The bar is very low for AD at this point and so far ANVS has the best data at 25 days. Assuming AD will get worse in placebo they should have better data then SAVA at 6 months.
News 
Market Data 
Discover 
